Economic burden of toxicities associated with treating metastatic melanoma in eight countries.

ABSTRACT:

Background

Information on costs of managing adverse events (AEs) associated with current treatments in metastatic melanoma is limited. This study estimates costs of AEs in eight countries: Australia (AU), Canada (CA), France (FR), Germany (GE), Italy (IT), the Netherlands (NL), Spain (ES), and the UK.

Methods

A literature search was conducted to identify grade 3/4 AEs from product label, published trials, conference abstracts, and treatment guidelines. Resource utilization for the management of each type of AE was determined via interviews with 5 melanoma clinicians in each country. Outpatient and inpatient costs were estimated for each type of AE using country-specific tariffs or government/published sources.

Results

In outpatient settings, the most costly AEs per in

SUBMITTER: Wehler E 

PROVIDER: S-EPMC5209401 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature